Beta cell glucose sensitivity identifies clinical response to disease-modifying therapies initiated at stage 3 type 1 diabetes onset
Authors' conclusion
Our results identified thresholds of change in βGS associated with a clinically significant impact on glycaemic management after intervention and suggest that baseline βGS in association with clinical and demographic parameters may be applied to identify individuals who are more likely to respond to an intervention.
Study context
- Population
- Participants in nine Phase II trials of disease-modifying therapies initiated at stage 3 T1D onset4,930 mixed meal tolerance test (MMTT) data points
- Participants
- 799 participants
Methodological detailsnine Phase II stage 3 T1D trials, model-derived βGS
- Nine Phase II stage 3 T1D trials
- Model-derived βGS
Primary result
As reported in the abstract
Predictors of βGS maintenance, HbA1c response and trial efficacy
- Older age and higher BMI associated with maintenance of βGS (loss <10% of baseline) and maintenance of HbA1c <53 mmol/mol (7.0%)
- Baseline βGS, age, HbA1c and insulin dose together predicted magnitude of effect on HbA1c after intervention
- Comparing positive and negative trials, normalised βGS was an earlier indicator of trial efficacy than C-peptide AUC
Original publication
Beta cell glucose sensitivity identifies clinical response to disease-modifying therapies initiated at stage 3 type 1 diabetes onset. Diabetologia. Published 12 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →